On 10 February 2026, Joyzyme Group Limited (8622), incorporated in the Cayman Islands, released an updated GEM information sheet. According to the document, the company was first listed on GEM on 13 December 2018, with RHB Capital Hong Kong Limited as its sponsor. The group’s business focuses on the research, development, manufacture, and sale of a range of in-vitro diagnostic (IVD) reagents and auxiliary reproductive supplies and equipment in the People’s Republic of China.

Executive Directors include Zhang Yujing, Zhou Xunyong, Zhang Chunguang, and Poon Lai Yin Michael, alongside Non-Executive Directors Bu Su and Xu Ming, and Independent Non-Executive Directors Chow Kwok Fai Joseph, Wang Yachun, and Tsui Wing Tak. The document notes Anselme Limited and Dr. Zhou Xunyong as substantial shareholders, each with a 50.35% interest in the company.

The company has 515,472,000 ordinary shares in issue at a par value of HK$0.01. The board lot size is 8,000 shares. An aggregate of 26,008,000 share options was granted in April 2020 under the Share Option Scheme, with an exercise price of HK$0.125 per share. Of those options, 19,000,000 were exercised and 7,008,000 have been forfeited, as stated in the document.

The group’s principal place of business in Hong Kong is located at Suite 1004, 10th Floor, Chinachem Golden Plaza, No. 77 Mody Road, Kowloon, and in Shenzhen at Building D, Shenzhen Junxuan, Dapeng New District. Its Hong Kong branch share registrar and transfer office is Tricor Investor Services Limited.